VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2020 | Migraine: CGRP mAbs efficacy measured over time

Dagny Holle-Lee • 20 May 2020
EAN 2020
Headache Antibodies
Prevention Treatment

Dagny Holle-Lee, MD, PhD, Essen University Hospital, Essen, Germany, talks on monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) an how patients can benefit from their effects within the first weeks of treatment. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Dagny Holle-Lee

0:58
Understanding migraines better with AI
Dagny Holle-Lee • 20 May 2020
0:59
Efficacy of galcanezumab in older patients with migraine
Dagny Holle-Lee • 20 May 2020

Related Videos

5:45
New European Academy of Neurology guidelines for cluster headache treatment
Rigmor Hojland Jensen • 19 Oct 2023
1:36
New cluster headache treatments are needed to better meet the needs of patients
Rigmor Hojland Jensen • 19 Oct 2023
3:17
Diagnostic criteria for trigeminal autonomic cephalalgias
Elizabeth Leroux • 18 Oct 2023
2:25
Challenges facing trigeminal autonomic cephalalgia diagnosis
Elizabeth Leroux • 18 Oct 2023
The content of VJNeurology is intended for healthcare professionals